BodyLogicMD’s menopause offer begins with symptoms and testing, then moves toward a personalized wellness plan. For someone asking specifically about oral progesterone, the important transition is between that broad process and a named medicine. Laboratory testing, membership access and a capsule label answer different questions.
Reviewed September 29, 2026, this assessment reads the menopause program, practitioner directory and pricing page together. It examines what a reader can establish before contacting the network and what must be confirmed with the selected practice. The review does not validate the provider’s comparative claims, diagnose a hormone deficiency or identify an appropriate treatment.
In this article
The program describes care rather than a standalone capsule purchase
The menopause page outlines testing, practitioner consultation, delivery of medication and ongoing support. It refers to estrogen and progesterone in its discussion of hormonal changes. That establishes a relevant clinical program; it does not establish a named oral product available to every person who completes the site’s initial questions.
The medicine-role guide helps keep the next step specific. A clinician should be able to explain what a proposed medicine is intended to do within the person’s treatment. A wellness plan may contain several recommendations, but the reasons for those recommendations should remain identifiable rather than being supplied by the program’s broad description.
A testing package is not the dispensing label
BodyLogicMD’s directory explanation describes extensive testing followed by a discussion with a practitioner. The pricing page also emphasizes laboratory findings. Those are descriptions of the service’s assessment process. A test result does not identify a capsule manufacturer, the ingredients in its shell or the formulation a pharmacy would prepare.
The public pages also do not prove that every test mentioned is necessary for every reader. Defy Medical’s review examines a consultation model with another broad menu. In each case, the useful question connects the proposed investigation to a clinical decision instead of treating the number of tests as a measure of medicine quality.
Bioidentical and compounded are not interchangeable labels
The network description favors customized compounded treatment and contrasts it with other hormone products. FDA’s menopause guidance states that approved medicines can also contain hormones identical to those produced naturally by the body. Molecular identity therefore does not tell a reader whether a preparation has FDA approval.
FDA separately explains that compounded drugs are not approved through its premarket drug review. The agency does not establish their safety, effectiveness and quality before marketing. This distinction does not inspect or condemn a particular pharmacy product. It prevents a broad description of customization from being mistaken for the approval record of a specific capsule.
The membership buys access at member prices
The Advantage pricing page displays $79 a month and describes a month-to-month membership that can be canceled. It identifies hormone panels and treatments as available at member pricing. That wording matters: a discount or purchasing arrangement is not the same as all laboratory work and medicine being included in the membership charge.
The reviewed page does not establish a complete oral-progesterone invoice or an exact capsule quantity. Nor does its cash-pay description verify personal insurance reimbursement. Hone Health’s review considers another service with separate membership and medication figures. The useful comparison names what each payment covers and leaves unquoted charges open.
The network needs a location-specific answer
The practitioner directory describes in-person and telemedicine care across a network. The reviewed information does not confirm a particular practitioner’s availability, acceptance of new patients or state-specific remote service for an individual reader. A network description cannot fill those gaps.
The selected practice also needs to identify who prescribes and who dispenses. A medicine may be shipped through a pharmacy relationship without the website establishing the exact pharmacy for one order. These are practical access questions, not conclusions about whether a reader should seek treatment. The network’s size and promotional claims do not supply a personal appointment or a verified capsule.
An ingredient question should reach the pharmacist intact
The capsule-excipients guide focuses on information missing from the reviewed BodyLogicMD program pages: the actual capsule’s inactive ingredients and how to obtain its complete record. A customized preparation is not automatically free of allergens or unwanted ingredients merely because it was made for an individual.
The FDA label for Prometrium names peanut oil and gelatin, with a peanut-allergy contraindication. It is a clear example of product-specific information, not proof that a BodyLogicMD pharmacy uses that formulation. The question should identify the particular prescription and pharmacy so the answer concerns the actual supplied medicine rather than progesterone in the abstract.
A clear follow-up discussion is more useful than a promised timeline
The pricing page describes expected symptom changes and ongoing adjustment. Those provider statements are not a prediction for a specific reader or evidence that one oral capsule will deliver the full advertised wellness outcome. A concern that persists, changes or appears during care still needs interpretation by the responsible professional.
The follow-up guide helps separate clinical reassessment, dispensing questions and membership administration. BodyLogicMD’s records support the existence of a menopause-care program, while the medicine’s exact identity and role remain unresolved. A useful response from the practice would name the preparation, explain its purpose and specify which professional handles questions after it is dispensed.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- BodyLogicMD: MenopauseProvider menopause service and attributed testing or outcome claims; not comparative clinical evidence · Checked 2026-09-29
- BodyLogicMD: Find a bioidentical hormone doctorProvider network and access description; no individual provider availability or exact capsule confirmed · Checked 2026-09-29
- BodyLogicMD: PricingProvider membership and member-pricing terms; membership does not include every test or treatment · Checked 2026-09-29
- FDA: MenopauseFederal patient information; clinical assessment, hormone-treatment risks and limits of bioidentical safety claims · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29